Jump to content
RemedySpot.com

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

Rate this topic


Recommended Posts

Posted

http://7thspace.com/headlines/367423/five_years_follow_up_following_two_or_three\

_doses_of_a_hepatitis_b_vaccine_in_adolescents_aged_11_15_years_a_randomised_con\

trolled_study.html

Five years follow-up following two or three doses of a hepatitis B vaccine in

adolescents aged 11-15 years: a randomised controlled study

The standard three-dose schedule of hepatitis B vaccines is frequently not

completed, especially in adolescents. A primary study has confirmed the

equivalence of a two-dose schedule of an Adult formulation of hepatitis B

vaccine [Group HBV_2D] to a three-dose schedule of a Paediatric formulation in

adolescents (11-15 years) [Group HBV_3D].

This follow-up study evaluated the five year persistence of antibody response

and immune memory against the hepatitis B surface (anti-HBs) antigens five years

after completion of primary vaccination.

Methods: A total of 234 subjects returned at the Year 5 time point, of which 144

subjects received a challenge dose of hepatitis B vaccine. Blood samples were

collected yearly and pre- and post-challenge dose to assess anti-HBs antibody

concentrations.

Results: At the end of five years, 79.5% (95% confidence interval [CI]:

71.7-86.1) and 91.4% (95% CI: 82.3-96.8) of subjects who received the two-dose

and three-dose schedules, respectively had anti-HBs antibody concentrations

>=10mIU/mL.

Post-challenge dose, all subjects had anti-HBs antibody concentration >=10mIU/mL

and >94% subjects had anti-HBs antibody concentration >=100mIU/mL. All subjects

mounted a rapid anamnestic response to the challenge dose.

Overall, the challenge dose was well-tolerated.

Conclusion: The two-dose schedule of hepatitis B vaccine confers long-term

immunogenicity and shows evidence of immune memory for at least five years

following vaccination.

Trial registration: Clinical Trials NCT00343915, NCT00524576

Author: Pierre Van Damme MoiseevaIgor MarichevAnne-Diane Kervyn

BooySherine Kuriyakose BrockwaySu-Peing NgMaarten LeyssenJeanne-Marie

Jacquet

Credits/Source: BMC Infectious Diseases 2010, 10:357

Posted

http://7thspace.com/headlines/367423/five_years_follow_up_following_two_or_three\

_doses_of_a_hepatitis_b_vaccine_in_adolescents_aged_11_15_years_a_randomised_con\

trolled_study.html

Five years follow-up following two or three doses of a hepatitis B vaccine in

adolescents aged 11-15 years: a randomised controlled study

The standard three-dose schedule of hepatitis B vaccines is frequently not

completed, especially in adolescents. A primary study has confirmed the

equivalence of a two-dose schedule of an Adult formulation of hepatitis B

vaccine [Group HBV_2D] to a three-dose schedule of a Paediatric formulation in

adolescents (11-15 years) [Group HBV_3D].

This follow-up study evaluated the five year persistence of antibody response

and immune memory against the hepatitis B surface (anti-HBs) antigens five years

after completion of primary vaccination.

Methods: A total of 234 subjects returned at the Year 5 time point, of which 144

subjects received a challenge dose of hepatitis B vaccine. Blood samples were

collected yearly and pre- and post-challenge dose to assess anti-HBs antibody

concentrations.

Results: At the end of five years, 79.5% (95% confidence interval [CI]:

71.7-86.1) and 91.4% (95% CI: 82.3-96.8) of subjects who received the two-dose

and three-dose schedules, respectively had anti-HBs antibody concentrations

>=10mIU/mL.

Post-challenge dose, all subjects had anti-HBs antibody concentration >=10mIU/mL

and >94% subjects had anti-HBs antibody concentration >=100mIU/mL. All subjects

mounted a rapid anamnestic response to the challenge dose.

Overall, the challenge dose was well-tolerated.

Conclusion: The two-dose schedule of hepatitis B vaccine confers long-term

immunogenicity and shows evidence of immune memory for at least five years

following vaccination.

Trial registration: Clinical Trials NCT00343915, NCT00524576

Author: Pierre Van Damme MoiseevaIgor MarichevAnne-Diane Kervyn

BooySherine Kuriyakose BrockwaySu-Peing NgMaarten LeyssenJeanne-Marie

Jacquet

Credits/Source: BMC Infectious Diseases 2010, 10:357

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...